Summary
SBIO Chart
Should You Invest in the ALPS Medical Breakthroughs ETF (SBIO)?
Designed to provide broad exposure to the Healthcare - Broad segment of the equity market, the ALPS Medical Breakthroughs ETF (SBIO) is a passively managed exchange traded fund launched on December 31, 2014.
SBIO: Biotech Breakthrough Opportunities Screened For Cash Burn
ALPS Medical Breakthroughs ETF targets late-stage clinical trial biotechs primed for outsized performance and M&A. SBIO's selective criteria focus on U.S.-listed firms with strong cash positions, Phase 2/3 assets, and near-term catalysts, creating a portfolio of high-volatility, high-alpha 'lottery tickets.' SBIO has delivered 111% returns over the past year, outperforming the S&P 500; its holdings have seen notable buyouts and clinical milestones.
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underlying index gained 10.01% in six trading days following its June 18 semi-annual rebalance.
ALPS Medical Breakthroughs ETF Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Jeff Ameen Spire Wealth Management | 53 | $2,724.74 | $3,455.6 | $730.86 | 26.82% |
 Ashley Buboltz Moran Wealth Management LLC | 29,348 | $1.21M | $1.89M | $679,923.27 | 56.09% |
 Christopher C. Powers Farther Finance Advisors, LLC | 4,978 | $164,084.17 | $324,565.6 | $160,481.43 | 97.8% |
| FTM F. Thomas Mosley Mosley Wealth Management | 37 | $1,936.58 | $2,348.2 | $411.62 | 21.25% |
 Michael Bailey MGB Wealth Management, LLC | 1,000 | $51,220 | $63,395 | $12,175 | 23.77% |
ALPS Medical Breakthroughs ETF (SBIO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ALPS Medical Breakthroughs ETF ever had a stock split?
ALPS Medical Breakthroughs ETF Profile
| ARCA Exchange | US Country |
Overview
The company operates a unique investment fund focusing on a niche within the biotechnology sector. Specifically, it employs a passive management or indexing approach to closely track the performance of an underlying index. This index is carefully selected to represent small and mid-cap biotechnology companies deeply involved in the clinical trial phase of their drug development, especially those in Phase II or Phase III stages as defined by the U.S. Food and Drug Administration (FDA) guidelines. By investing at least 80% of its net assets in securities that comprise the underlying index, the fund aims to provide investors with a focused exposure to the biotechnology sector's potential growth, rooted in its innovative and clinical advancements.
Products and Services
- Passive Management Investment Fund
- Exposure to Small and Mid-Cap Biotechnology Companies
- Customized Index Tracking
This service involves the operation of an investment fund that adopts a passive management or indexing investment strategy. The fund is designed to mirror the performance of its underlying index, which is constituted of small and mid-cap biotechnology companies. These companies are significantly involved in developing drugs that are currently undergoing Phase II or Phase III clinical trials as stipulated by the FDA. This strategy is particularly suited for investors looking to gain exposure to the biotechnology sector's dynamics without actively managing their investments.
Through its targeted investment strategy, the fund offers investors a unique opportunity to invest in small and mid-cap biotechnology companies. This segment is known for its significant growth potential and innovative approaches to drug development. The selection criteria ensure that only companies with drugs in the critical Phase II or Phase III of FDA clinical trials are included, aligning investors with those poised for potential breakthroughs and market impact.
The fund's investment approach is characterized by the creation and tracking of a customized index. This index is carefully constructed to represent a portfolio of biotechnology companies engaged in advanced stages of clinical trials, ensuring a focused and strategic exposure to the sector. This method provides a transparent and efficient way for investors to tap into the biotechnological innovations and advancement, reflecting an in-depth understanding of this market segment's opportunities and risks.
